The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,296.00
Bid: 1,286.00
Ask: 1,292.00
Change: 0.00 (0.00%)
Spread: 6.00 (0.467%)
Open: 1,296.00
High: 1,296.00
Low: 1,274.00
Prev. Close: 1,296.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM and Q1 Interim Management Statement

12 Feb 2021 07:00

RNS Number : 8764O
Victrex PLC
12 February 2021
 
 

 

12 February 2021

Victrex plc - AGM and Q1 Interim Management Statement

'Positive start but variable improvement trend; full year expectations unchanged'

Victrex plc, an innovative world leader in high performance polymer solutions, releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting (AGM) being held today. Q1 covers the period 1 October to 31 December 2020.

Overall, the Group saw a positive start to FY 2021. Although Q1 was slightly ahead of our expectations, performance remains variable by end market. Asia is seeing the most incremental improvement on a geographic basis, with a mixed performance in Europe and the US.

For Q1 as a whole, Group revenue of £68.7m was 1% ahead of the prior year (Q1 2020: £67.7m), with Q1 Group sales volume of 883 tonnes also being 1% ahead of the prior year (Q1 2020 877 tonnes). Since the 1 October 2020, FY 2021 on a year-to-date (YTD) basis is slightly lower than the prior year, reflecting January being robust but lower than the prior year.

End market performance

Across our end-markets, trading saw an incremental improvement from the low point of H2 2020, with Electronics being notably strong as increased homeworking supports demand for a range of smart devices. Performance in Automotive, Medical and Value Added-Resellers was broadly stable compared to the prior year period, with Automotive benefiting from new application growth and some cyclical recovery, and Medical continuing to see a gradual improvement in procedures, largely in Asia. Whilst Energy saw some limited improvement from the low point of H2 2020, performance was lower than the prior year period. Aerospace remains challenging on a short-term basis.

Mega-programmes

As previously communicated, we continue to see little evidence of any material slowdown in our pipeline of 'mega-programmes'. We remain fully focused on delivering specific milestones as we move closer to greater commercialisation.

 

Financial position

Victrex retains a highly cash generative business model, with our cash position improving since the end of FY 2020. Net cash of £84.4m at 31 December 2020 excludes cash ringfenced for our Panjin VYX facility in China, in what will be a year of high capital expenditure totalling up to £50m for the Group.

Brexit, inventory and supply chain

Following the Brexit trade agreement, which took effect from January 1st 2021, the Group has seen no material issues in its supply chain. High service levels are being maintained for customers, with continued tariff free access into the EU.

Whilst our inventory levels remain high, we are on plan to unwind sales inventory through the remainder of FY 2021, which will start to benefit our working capital position.

COVID-19

 

We have sustained our proactive approach to managing the impact of COVID-19 with the safety, health and well-being of Victrex employees being our highest priority. Our COVID contingency plans remain in place and our supply chain has been unaffected, enabling us to continue to meet our customers' needs in full. Our financial position remains strong and the outlook is starting to improve as some signs of recovery emerge in several of our end markets.

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "This is a positive start to FY 2021 and we continue to see incremental improvement across several of our end markets.

"Nevertheless, the incremental improvement trend may remain variable and our assumptions are that we will still see a weaker first half overall, compared to H1 2020 which ended strongly. Consequently, at this early stage, our full year expectations are unchanged.

"Our priorities remain the health, safety and well-being of our employees and delivering strong service levels for our customers. With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

Analyst & investor conference call

A conference call with management will take place this morning, Friday 12th February 2021, at 0830am GMT via +44 (0) 3333 000804 and PIN 24673921#. A replay of the call is also available at +44 (0) 333 300 0819 and PIN 301336320#.

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUARURAAUUAUR
Date   Source Headline
11th Oct 20167:00 amRNSTrading Statement
30th Sep 20161:11 pmRNSTotal Voting Rights
19th Sep 20164:28 pmRNSDirector/PDMR Shareholding
19th Sep 20163:18 pmRNSHolding(s) in Company
31st Aug 20169:28 amRNSTotal Voting Rights
17th Aug 20163:46 pmRNSDirector/PDMR Shareholding
29th Jul 20162:47 pmRNSTotal Voting Rights
28th Jul 20162:57 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSInterim Management Statement
19th Jul 20164:34 pmRNSDirector/PDMR Shareholding
30th Jun 201610:00 amRNSTotal Voting Rights
17th Jun 20163:56 pmRNSDirector/PDMR Shareholding
14th Jun 20164:42 pmRNSHolding(s) in Company
14th Jun 20164:24 pmRNSHolding(s) in Company
1st Jun 20169:02 amRNSBlock listing Interim Review
31st May 201611:42 amRNSTotal Voting Rights
26th May 20164:26 pmRNSHolding(s) in Company
17th May 20164:11 pmRNSDirector/PDMR Shareholding
16th May 20167:00 amRNSHalf-year Report
3rd May 20163:27 pmRNSHolding(s) in Company
3rd May 20163:15 pmRNSHolding(s) in Company
3rd May 20163:00 pmRNSHolding(s) in Company
29th Apr 201610:00 amRNSTotal Voting Rights
28th Apr 20167:00 amRNSResolution of US FTC inquiry
21st Apr 20167:00 amRNSDirector Declaration
19th Apr 201611:07 amRNSDirector/PDMR Shareholding
7th Apr 20167:00 amRNSTrading Statement
31st Mar 20162:51 pmRNSTotal Voting Rights
31st Mar 20161:45 pmRNSTotal Voting Rights
17th Mar 201610:15 amRNSDirector/PDMR Shareholding
1st Mar 20165:00 pmRNSDirector/PDMR Shareholding
29th Feb 20162:18 pmRNSTotal Voting Rights
26th Feb 20163:09 pmRNSHome Member State
17th Feb 201611:27 amRNSDirector/PDMR Shareholding
10th Feb 20163:55 pmRNSResult of AGM
10th Feb 20167:00 amRNSAGM Statement
9th Feb 20164:44 pmRNSHolding(s) in Company
5th Feb 20161:38 pmRNSGrant of Options
29th Jan 20169:27 amRNSTotal Voting Rights
19th Jan 201611:39 amRNSDirector/PDMR Shareholding
19th Jan 201610:08 amRNSDirector Declaration
5th Jan 201612:00 pmRNSAnnual Financial Report
31st Dec 201510:00 amRNSTotal Voting Rights
17th Dec 20154:23 pmRNSHolding(s) in Company
17th Dec 20153:36 pmRNSDirector/PDMR Shareholding
16th Dec 20154:37 pmRNSDirector/PDMR Shareholding
15th Dec 201512:03 pmRNSDirector/PDMR Shareholding
9th Dec 20152:34 pmRNSDirector/PDMR Shareholding
8th Dec 20154:43 pmRNSHolding(s) in Company
8th Dec 20157:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.